Nanobody-based chimeric antigen receptor T cells designed by CRISPR/Cas9 technology for solid tumor immunotherapy

Chimeric antigen receptor-based T-cell immunotherapy is a promising strategy for treatment of hematological malignant tumors; however, its efficacy towards solid cancer remains challenging. We therefore focused on developing nanobody-based CAR-T cells that treat the solid tumor. CD105 expression is...

詳細記述

保存先:
書誌詳細
出版年:Signal Transduct Target Ther
主要な著者: Mo, Fengzhen, Duan, Siliang, Jiang, Xiaobing, Yang, Xiaomei, Hou, Xiaoqiong, Shi, Wei, Carlos, Cueva Jumbo Juan, Liu, Aiqun, Yin, Shihua, Wang, Wu, Yao, Hua, Yu, Zihang, Tang, Zhuoran, Xie, Shenxia, Ding, Ziqiang, Zhao, Xinyue, Hammock, Bruce D., Lu, Xiaoling
フォーマット: Artigo
言語:Inglês
出版事項: Nature Publishing Group UK 2021
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7904846/
https://ncbi.nlm.nih.gov/pubmed/33627635
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41392-021-00462-1
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料